Funding Will Support Clinical Trials of Procyrion's Aortix Heart Pump

January 30, 2018—Procyrion, Inc., a clinical-stage medical device company based in Houston, Texas, announced the completion of a $16 million Series C funding round. Procyrion plans to use the proceeds for clinical development of its Aortix heart pump, which is a catheter-deployed, intra-aortic pump designed for ambulatory use. The funding will advance the Aortix device into pilot trials in acutely decompensated heart failure patients and will be used to further enhance the features and performance of the Aortix system, the company stated.

According to Procyrion, the Aortix device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. The device, which is not approved for use or sale, was conceived by cardiologist Reynolds M. Delgado III, MD, who is Medical Director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute in Houston, Texas.

The funding round was led by an affiliate of Fannin Partners. Returning investors include Scientific Health Development, the State of Texas, and an undisclosed strategic investor. To date, Procyrion has raised more than $29 million in funding.